GlassScriptPhysician profile
Jeffrey B Goudreau
NPI 1932179314
$1,705.14
in general payments reported to CMS, 2019-2025
21 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $330 · 2021: $72.06 · 2022: $230 · 2023: $151 · 2024: $170 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $262.72 | 2021-2024 | |
| Amarin Pharma, INC. | $262.55 | 2019-2020 | |
| Astellas Pharma US INC | $210.49 | 2019-2023 | Veozah |
| Amgen INC. | $177.77 | 2020-2025 | Krystexxa |
| Genentech USA, INC. | $128.84 | 2019 | |
| Pfizer INC. | $119.09 | 2022-2025 | |
| Medtronic Vascular, INC. | $100.00 | 2020 | |
| Glaxosmithkline, LLC. | $87.64 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $70.55 | 2025 | Freestyle Libre 3, Esprit |
| Sumitomo Pharma America, INC. | $49.87 | 2024-2025 | Gemtesa |
| Novo Nordisk INC | $46.55 | 2022-2025 | Wegovy |
| Inari Medical, INC. | $28.21 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mayne Pharma Commercial LLC | $27.46 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.58 | 2025 | Jascayd |
| Madrigal Pharmaceuticals | $21.68 | 2024 | Resmetirom |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $19.69 | 2025 | Rexulti |
| Renalytix Ai, INC. | $15.98 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Janssen Pharmaceuticals, INC | $14.24 | 2021 | |
| Antares Pharma, INC. | $14.22 | 2025 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $12.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Goudreau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.